Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon.
Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.
Mechanism of action for leflunomide in rheumatoid arthritis.
How integrated are neurology and palliative care services? Results of a multicentre mapping exercise.
The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis.
Cognitive Impairment in Multiple Sclerosis: Clinical Manifestation, Neuroimaging Correlates, and Treatment.
'Clinically definite benign multiple sclerosis', an unwarranted conceptual hodgepodge: evidence from a 30-year observational study.
CNS vasculitis in a patient with MS on daclizumab monotherapy.
Clinical proteomics of enervated neurons.
Polymorphism in Leptin and Leptin Receptor Genes May Modify Leptin Levels and Represent Risk Factors for Multiple Sclerosis.
Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin.
UCSF Seminar: "How do we get a myelinated brain? A new model for distribution of oligodendrocytes throughout the developing CNS"
Bioengineered cell culture systems of central nervous system injury and disease.
Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a.
Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion.
Use of rituximab in multiple sclerosis: current progress and future perspectives.
Primary Progressive MS evolving from Radiologically Isolated Syndrome.
Flupirtine as Oral Treatment in Multiple Sclerosis (FLORIMS)
Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?
Is No Evidence of Disease Activity a Realistic Goal for Patients With Multiple Sclerosis?
Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis.
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Biomarkers of disease activity in multiple sclerosis.
WT1 and interferon-β-vitamin D association in MS: a longitudinal study.

Pages